Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. - Wikidata - wikimedia - TriplyDB

Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice.

Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice.

http://www.wikidata.org/entity/Q46010720

about

On ceramides, other sphingolipids and impaired glucose homeostasis Lipid microdomain modification sustains neuronal viability in models of Alzheimer's disease Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase Sphingolipids and phospholipids in insulin resistance and related metabolic disorders.Redox control of liver function in health and disease Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms Ganglioside GM3 Mediates Glucose-Induced Suppression of IGF-1 Receptor-Rac1 Activation to Inhibit Keratinocyte Motility.ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease.Neuronal expression of glucosylceramide synthase in central nervous system regulates body weight and energy homeostasis.Correction of liver steatosis by a hydrophobic iminosugar modulating glycosphingolipids metabolism.Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars.Endoplasmic reticulum heat shock protein gp96 maintains liver homeostasis and promotes hepatocellular carcinogenesis.Ceramides as modulators of cellular and whole-body metabolism siRNA-based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown.Identification of Ganglioside GM3 Molecular Species in Human Serum Associated with Risk Factors of Metabolic Syndrome Modulation of sphingolipid metabolism with calorie restriction enhances insulin action in skeletal muscle.Altered distribution of regulatory lymphocytes by oral administration of soy-extracts exerts a hepatoprotective effect alleviating immune mediated liver injury, non-alcoholic steatohepatitis and insulin resistance.Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels.Fenretinide prevents lipid-induced insulin resistance by blocking ceramide biosynthesis Prepartum body condition score and plane of nutrition affect the hepatic transcriptome during the transition period in grazing dairy cows.Ganglioside GM3 depletion reverses impaired wound healing in diabetic mice by activating IGF-1 and insulin receptors.Synthesis of a novel photoactivatable glucosylceramide cross-linker.Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance.β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model.Elevated plasma sphingomyelin (d18:1/22:0) is closely related to hepatic steatosis in patients with chronic hepatitis C virus infection.Glucosylceramide synthase in the fat body controls energy metabolism in Drosophila.Hepatic glycosphingolipid deficiency and liver function in mice.Adeno-associated virus-mediated expression of acid sphingomyelinase decreases atherosclerotic lesion formation in apolipoprotein E(-/-) mice.Impaired liver regeneration by β-glucosylceramide is associated with decreased fat accumulation.Inhibition of glucosylceramide synthase stimulates autophagy flux in neurons.

P2860

Q27021446-CBA0A868-C046-4682-BFB4-AD98757E0F8D Q28278644-B74B6620-D0EF-4242-A1F5-ECDE0F7634FF Q28474576-93846125-0F25-4EEC-84F4-E0826357FAE1 Q30241943-04B9EDB6-44C3-429B-A255-4241F7BAEC34 Q33830140-8ACE5443-38E1-4FE1-ADA8-67C4FEC20265 Q33843550-82223A7B-3AB9-4064-9B40-38B7D65CDE80 Q33878505-FF4BB834-D2DE-40AD-91A0-14A5AA234081 Q34273177-551D859B-CEAC-4168-ADEF-5A0A7573E027 Q34336991-2BB6D9F1-4163-4D40-BAD5-AA01AD507AD0 Q34440771-FAA73745-9153-4372-8CC8-5E258C1E9F86 Q35181892-A1F32634-0FC9-4724-9F59-F7CCC9FA9666 Q35204677-44B2BA61-DD90-4062-975F-8579673E566E Q35484864-B055A864-2190-41A3-A4F4-C8A203E01916 Q35590281-23E740BD-A02B-418B-AF3C-DD9A787AAEE2 Q35671752-5CF6136D-30AF-491F-8571-5AD1C7975967 Q35706788-A253627F-165F-4897-9517-4F926635535C Q35783896-118E1498-12E2-466E-8DFC-CEE4AC075226 Q35997786-21EF23F9-5BB9-464A-AFC7-B70C034412C6 Q36006997-4414944D-B1A1-461A-9B1B-FC56C2358234 Q36180569-39CAB107-4B45-4E9C-A572-E6B8D6967A9E Q37707054-B1F6C33A-BF93-4A7C-A1A7-85D295EC1AB6 Q38758310-86C20D95-8A22-48A4-BE2F-6B3D896870D2 Q38833111-40788DD3-7D20-4C26-83AF-BFEE96CB7B84 Q42066264-15768219-74A8-45A1-B7CF-8119B4FF21C7 Q42219793-CDAED153-50C6-4A03-8E61-219A2017C17A Q42773443-CC0CD173-5129-4B35-8E2D-48542D1C7B31 Q43078747-93FC1C25-7C21-43BF-8318-37E1800A6471 Q45365704-4C0D3E30-A81E-4FBE-AF21-3542C2EFFD0F Q51075878-E8ADC916-D15B-4CC5-9DEE-06EC5FC83D39 Q51754932-100E3B43-1A84-45F2-9DDA-D874F1A767D8

P2860

Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice.

http://www.wikidata.org/entity/Q46010720

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice.

@en

Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice.

@nl

type

label

Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice.

@en

Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice.

@nl

prefLabel

Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice.

@en

Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice.

@nl

P1433

Q46010720-43B68147-C301-4378-A899-5C0165E7EF95

P1476

Q46010720-8647A51B-4B14-4236-B785-E9D9AA02E128

P2093

Q46010720-3277E830-AD71-45B2-90A5-4E69BF480B6F

Q46010720-47FC46EA-ED21-4734-959E-6B8D4651727D

Q46010720-49569342-38C4-49D5-9EF4-4F5FB37C3AB0

Q46010720-4A00FAE8-47B4-4E25-AAC0-D8DEAB1C9ABC

Q46010720-4C4E2635-319B-436E-8902-BDE451CC409B

Q46010720-500CCFC7-AA33-4825-95A0-CF272D2068C5

Q46010720-739A0284-8F5A-4022-BA88-13BB0C21ABDA

Q46010720-85B897C4-1E42-4416-BD33-A4FA2AAF09B0

Q46010720-88B6FF98-52F1-47F2-920A-B14A657F3829

Q46010720-90B66DAE-1908-487A-8553-9AEABE328126

P2860

Q46010720-0A4D29F9-AFD5-4F77-BF1D-2AEA20D8213D

Q46010720-1130F4BC-9FEA-40E8-A530-39C1B0E4EF1B

Q46010720-44536581-2993-4EAF-B36A-5E473052743C

Q46010720-53A61B39-4210-4ADF-9002-B3C546D851C0

Q46010720-62BFAD7E-E3EC-4BC3-A576-EBCAD252DD5C

Q46010720-6A649A98-9E33-4A73-8025-D9B588248C4A

Q46010720-6CEB5BF3-24CD-44BA-99F3-4A55C33A2231

Q46010720-6F9F7E71-9F83-4811-A748-FCBACAF2AE9B

Q46010720-72122728-C70B-45D9-8FFD-69B5E6794762

Q46010720-7FE0815E-43D7-4739-B5AF-17D7916068DE

P304

Q46010720-38E0BB5C-7B71-4A6C-8D97-58B4AF4C14D7

P31

Q46010720-30A5DD0D-421D-4E20-971C-2EBB5E6BA592

P356

Q46010720-60D4771B-5A92-4391-A21B-815D41AD7BD1

P407

Q46010720-BB5F53B1-D56A-462A-AA21-E2DE0B3D204B

P433

Q46010720-B885152F-2F12-41EC-95AC-C4A6C0EA00ED

P478

Q46010720-7C701FD7-8BB9-4D8A-8CE7-712F3B96C89D

P577

Q46010720-5FC1D706-426E-487E-85CC-88148524FBF0

P5875

Q46010720-AFFD78F3-FE66-41AB-A8B4-4A667E9B8D5E

P698

Q46010720-E0FF48D0-0536-4A2F-9A2E-A7EDCF041A42

P921

Q46010720-0CD3703C-2425-4400-A139-A6B2F5C015CE

P356

P1433

P1476

Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice.

@en

P2093

Canwen Jiang

http://www.w3.org/2001/XMLSchema#string

Cynthia Arbeeny

http://www.w3.org/2001/XMLSchema#string

Diane Copeland

http://www.w3.org/2001/XMLSchema#string

Hongmei Zhao

http://www.w3.org/2001/XMLSchema#string

I-Huan Wu

http://www.w3.org/2001/XMLSchema#string

James A Shayman

http://www.w3.org/2001/XMLSchema#string

Jinhua Zhang

http://www.w3.org/2001/XMLSchema#string

Johannes M Aerts

http://www.w3.org/2001/XMLSchema#string

Joshua Pacheco

http://www.w3.org/2001/XMLSchema#string

Malgorzata Przybylska

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammation and insulin resistance

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome

Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity

Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Enhanced insulin sensitivity in mice lacking ganglioside GM3.

Nonalcoholic fatty liver disease: from pathogenesis to patient care.

Nonalcoholic fatty liver disease as a complication of insulin resistance.

Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment.

P304

85-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.22970

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24429860

http://www.w3.org/2001/XMLSchema#string

P698

19444873

http://www.w3.org/2001/XMLSchema#string

P921